Jan 16 (Reuters) - U.S. private equity firm Hellman &
Friedman is in early-stage talks for a potential sale of medical
devices maker Cordis ( JNJ ), seeking a value of over $9 billion,
Bloomberg News reported on Friday, citing people familiar with
the matter.
About half a dozen publicly traded medical device companies
are currently evaluating potential bids for Cordis ( JNJ ), the report
added.
Hellman & Friedman bought Cordis ( JNJ ) from Cardinal Health in
2021 for about $1 billion, six years after Johnson & Johnson
sold it.
Cordis ( JNJ ) is known for making cardiovascular devices such as
catheters and stents.
H&F declined to comment. Cordis ( JNJ ) and one of its investors KKR
did not immediately respond to Reuters' requests for
comment outside of regular business hours.